Becton Dickinson and Co  

(Public, NYSE:BDX)   Watch this stock  
Find more results for BDX
161.26
-0.67 (-0.41%)
Apr 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 159.81 - 161.32
52 week 128.87 - 162.98
Open 161.01
Vol / Avg. 0.00/878,467.00
Mkt cap 34.02B
P/E 49.39
Div/yield 0.66/1.64
EPS 3.27
Shares 211.82M
Beta 0.97
Inst. own 86%
May 5, 2016
Q2 2016 Becton Dickinson and Co Earnings Release - 9:30AM EDT - Add to calendar
May 5, 2016
Q2 2016 Becton Dickinson and Co Earnings Call - 8:00AM EDT - Add to calendar
Mar 15, 2016
Becton Dickinson and Co at Barclays Global Healthcare Conference - Webcast
Feb 24, 2016
Becton Dickinson and Co at RBC Capital Markets Healthcare Conference
Feb 3, 2016
Q1 2016 Becton Dickinson and Co Earnings Release
Feb 3, 2016
Q1 2016 Becton Dickinson and Co Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 7.67% 6.76%
Operating margin 11.79% 10.45%
EBITD margin - 23.25%
Return on average assets 3.50% 3.57%
Return on average equity 12.77% 11.38%
Employees 49,517 -
CDP Score - 94 B

Address

1 Becton Dr
FRANKLIN LAKES, NJ 07417-1815
United States - Map
+1-201-8476800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates through two business segments: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. The Company's products include hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; BD Vacutainer brand blood collection products, and flow cytometry instruments and reagents.

Officers and directors

Vincent A. Forlenza Chairman of the Board, President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Christopher R. Reidy Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Age: 58
Bio & Compensation  - Reuters
William A. Kozy Chief Operating Officer, Executive Vice President
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jerome V. Hurwitz Chief Human Resource Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Gary M. Cohen Executive Vice President and President, Global Health.
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Alexandre Conroy Executive Vice President and President, Europe, EMA
Age: 52
Bio & Compensation  - Reuters
James Lim Executive Vice President and President, Greater Asia
Age: 51
Bio & Compensation  - Reuters
Thomas E. Polen Executive Vice President and President - Medical
Age: 42
Bio & Compensation  - Reuters
Ellen Strahlman M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Linda M. Tharby Executive Vice President and President - Life Sciences
Age: 47
Bio & Compensation  - Reuters